Results 51 to 60 of about 4,212 (173)
Sex Differences in Medication Discontinuation in Axial Spondyloarthritis
Arthritis Care &Research, Volume 78, Issue 7, Page 914-924, July 2026.Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall +9 more
wiley +1 more source
RMD Open, 2020 Objectives In axial spondyloarthritis (axSpA), higher body mass index (BMI) is associated with worse outcomes including response to biologics. Further clarity is needed on whether BMI is associated with disease activity overall, independent of treatment ...
Lianne S Gensler +4 more
doaj +1 more source
International Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail +7 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Ankylosing spondylitis (AS) is a chronic immune‐mediated inflammatory arthropathy primarily affecting the axial skeleton but may involve peripheral joints, particularly the hips. Avascular necrosis (AVN) of the femoral head represents a severe, underrecognized complication whose pathogenesis in AS is multifactorial—encompassing disease ...
Syeda Simrah Shah +5 more
wiley +1 more source
Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts [PDF]
Clinical Rheumatology, 2011 The availability of population-specific normative data regarding disease severity measures is essential for patient assessment. The goals of the current study were to characterize the pattern of ankylosing spondylitis (AS) in Portuguese patients and to develop reference centile charts for BASDAI, BASFI, BASMI and mSASSS, the most widely used assessment
Pimentel-Santos, Fernando M. +17 more
openaire +7 more sources
Rheumatology &Autoimmunity, Volume 6, Issue 2, Page 105-117, June 2026.This cross‐sectional study enrolled Thai patients with spondyloarthritis to assess the prevalence and its impact. Fibromyalgia was present in 5.5% and significantly impaired health‐related quality of life and symptom perception. Low disease activity, good sleep quality, and FS < 3 were independently associated with achieving PASS.
Sittikorn Srivorrapattarakul +1 more
wiley +1 more source
International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran +9 more
wiley +1 more source
Patient‐reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID‐19 Pandemic
ACR Open Rheumatology, 2020 Objective Response to the coronavirus disease 2019 (COVID‐19) pandemic has resulted in shelter‐in‐place orders and major changes to individuals’ daily lives.
Jean W. Liew +5 more
doaj +1 more source
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis [PDF]
Annals of the Rheumatic Diseases, 2004 TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS).To identify parameters predicting the clinical response to TNF blockers in AS.Patients with active AS participated in two placebo controlled, randomised trials conducted in Germany with infliximab (n = 69) and etanercept (n = 30), respectively.
M, Rudwaleit +4 more
openaire +2 more sources
ACR Open Rheumatology, Volume 8, Issue 5, May 2026.Objective Proadrenomedullin (pro‐ADM) is a peptide implicated in immunomodulation, with higher levels observed in inflammatory conditions, cardiovascular impairment, and sepsis. Although extensively studied in acute disorders, its potential as a biomarker in inflammatory arthritis remains underexplored.
Nefeli Stavroula Papastathopoulou +10 more
wiley +1 more source